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Role of the Extended Lymphadenectomy in Gastric Cancer Surgery: Experience 
in a Single Institution 
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A. Martínez-Gonzalez, and Javier A.-Cienfuegos. 
Background: Although curative resection is the treatment of choice for gastric cancer, contro-
versy exists about the adequate extent of lymph node dissection when resection is performed. 
Methods: We retrospectively assessed 85 patients who underwent a limited lymphadenectomy (D1) and 71 who had an extended lymph node dissection (D2) in a single institution between 
1990 and 1998 (median follow-up, 37.3 months). Prognostic factors were assessed by Cox 
proportional hazard models adjusted for potential confounders. 
Results: We found no significant difference in the length of hospital stay (median, 12.1 and 
13.1 days), overall morbidity (48.2% and 53.5%), or operative mortality (2.3% and 0%) 
between D1 and D2, respectively. Five-year survival in the D2 group was longer (50.6%) than 
in the D1 group (41.4%) for tumor stages (tumor-node-metastasis) >I. In multivariate analysis, 
tumor-node-metastasis stage (hazard ratio for stages >I vs. 0–I, 11.6), the ratio between 
invaded and removed lymph nodes, the presence of distant metastases, Laurén classification, 
and the extent of lymphadenectomy (hazard ratio for D1 vs. D2, 2.3; 95% confidence interval, 
1.25–4.30) were the only significant prognostic factors. 
Conclusions: Our experience shows that extended (D2) lymph node dissection improves 
survival in patients with resected gastric cancer. 
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Gastric cancer is the 4th cause of tumoral death in Europe,1 and it is considered the 10th in 
the United States. These figures increase 6-fold in Japan, where early detection is becoming 
increasingly important. Japanese authors2,3 report survival results significantly better than those 
in Western series, on the basis of the concept of extended lymphadenectomy (EL). 
In 1981, the Japanese Research Society for Gastric Cancer4 proposed D2 lymphadenectomy 
as the proper treatment for gastric cancer; this involved radical gastrectomy with level 2 lymph 
node dissection. Since then, Western groups5,6 have not reproduced Japanese results in 
terms of survival and complications. They have found no difference between limited 
lymphadenectomy and EL, as two large multicenter randomized studies have shown.7,8 
However, these studies had problems of protocol violations (incomplete or more extensive 
lymph node dissections in the different study groups), a high morbidity/mortality rate 
because there were a large number of experiences in different hospitals, and, at times, an 
unnecessary extent of organ resection (that includes the excision of the tail of the pancreas). 
The aim of this study was to investigate the role of extended (D2) lymph node dissection in a 
group of patients undergoing surgery in a single institution, thus avoiding the problem of 
protocol violations associated with multicenter prospective trials.7–9 
 
 
 
 
 
 
 
 
 
METHODS 
We analyzed 156 consecutive patients with resected adenocarcinoma of the stomach 
operated on between January 1991 and June 1998 in a single institution by three surgeons. 
We divided patients into two well-balanced groups. The D1 group (85 patients) was submitted 
to a gastrectomy with N1 level lymph node dissection4 (major and lesser curvature, supra and 
subpyloric lymph nodes, and paracardial nodes when total gastrectomy was performed). The 
D2 group (71 patients) was submitted to a total gastrectomy with EL that included the N1 and 
N2 lymph node levels (removal of the lymph nodes along the left gastric, common hepatic, and 
splenic arteries; celiac axis; and splenic hilus), hepatoduodenal ligament (level 12 in the 
Japanese Research Society for Gastric Cancer classification, including lymph nodes along the 
portal vein and proper hepatic artery), and sampling of the level N3 and N4 lymph nodes (para-
aortic, retropancreatic, and mesenteric nodes). 
Although we did not use a randomized design, we did not follow a biased assignment of 
patients to one or another procedure. Changes in recruitment were due to skepticism about EL 
results reported in different published series.10–12 
We included resectable patients with any tumor stage (1997 tumor-node-metastasis 
classification13), except for those with macroscopic distant metastases (bone, hepatic, lung, or 
peritoneal) and any location, excluding esophageal tumors, affecting the stomach. Patients 
with positive peritoneal lavage (two cases in D1 and four cases in D2), affected 
hepatoduodenal lymph nodes, or localized carcinomatosis at the bursa omentalis (one patient 
in the D2 group) were also included. 
Table 1 shows the characteristics of both groups. They differ only in age (8 years younger in 
the D2 group), type of gastrectomy (56.5% of patients in the D1 group were submitted to a 
subtotal gastrectomy vs. none in D2), American Society of Anesthesiologists (ASA) index,14 
and associated radiotherapy. All these features were properly included in a multivariate model 
to determine their prognostic value and to control for potential confounding. 
Splenectomy was performed every time that total gastrectomy was performed, adding distal 
pancreatectomy, hepatic wedge resection, or partial colectomy only when the surgeon 
observed macroscopic invasion of these organs. We divided postoperative complications into 
general (including pleuropulmonary complications [acute lung edema, pleural effusion, atelecta-
sis, pneumothorax, and pneumonia], cardiac complications, phlebitis, sepsis derived from 
central line infection, and urine infection) and specific (hemorrhage, abscess, fistula, 
anastomosis dehiscence, esophageal stenosis, incisional hernia, diarrhea, paralytic ileus, 
dumping, and cholestasis) complications.  
The median follow-up was 37.3 months (25th–75th percentile, 16.3–61.5 months), continued 
until March 2000, and was complete for all the patients in the study. At the end of this study, 
39 patients of the D1 group and 25 patients of the D2 group had died. The remaining 92 
patients (46 in D1 and 44 in D2) had no evidence of disease. 
End Points 
Once confirmed that we had two well-balanced groups of patients, one receiving limited 
lymphadenectomy (D1 operation) and the other an extended lymph node dissection (a 
modified D2 operation), our purposes were the following. 
1. To detect differences in morbidity and hospital mortality between groups. 
2. To determine whether one group had a better survival rate. 
3. To identify the independent prognostic factors affecting survival, applying a multivariate 
Cox model. 
 
 
 
 
 
 
 
 
 
 
 
Statistical Analysis 
Analyses were performed with SPSS 9.0 for Windows (SPSS Inc., Chicago, IL). P < .05 
(two sided) was considered statistically significant. The X2 test or Fisher’s exact test was 
used to compare qualitative variables. Student’s t-test (mean and SD) was used for 
quantitative variables if they were assumed to follow a normal distribution; quantitative 
nonnormal variables were compared by using the Mann-Whitney U-test or the Kruskal-
Wallis test. The effect of each prognostic variable was studied in univariate analyses by 
using the log-rank test; variables with a P value of <.25 were considered candidates to 
enter a multivariate Cox regression model15 and were stratified for pathologic tumor stage. 
RESULTS 
We found no significant difference in overall hospital morbidity (48.2% of patients in D1 and 
53.5% in D2; P = .511) or length of hospital stay (D1: median, 12.1 days; 25th–75th percentile, 
10.0–19.2 days; D2: median, 13.1 days; 25th –75th percentile, 11.0–17.0 days; P = .306) 
between the groups (Table 2). Nevertheless, the durations of surgery (mean: 202.9 minutes in 
D2 vs. 187.7 minutes in D1; P = .035), daily production (161.8 ml in D2 vs. 105.8 ml in D1; P < 
.001), and maintenance of drains (9.9 days in D2 vs. 9.2 days in D1) were longer in the D2 
group. 
No significant difference was observed in general (14.1% in D1 vs. 8.4% in D2; P = .269), 
nor were there specific complications (34.1% in D1 vs. 45.0% in D2; P = .162) between 
groups (Table 2). Operative mortality (30-day mortality rate) was 2.3% in D1 and 0% in D2 (P 
= .295). Mortality due to causes other than gastric carcinoma (related to radiotherapy or 
chemotherapy treatment or intercurrent benign or malignant diseases) occurred in eight D1 
patients and two D2 patients. 
Once specific complications were studied (Table 2), hemorrhage was found in D1 more 
frequently than in D2 (five patients, due to bleeding through the nasogastric tube at 
gastroenteroanastomosis). We found that 40% of the D2 patients with a pancreatic fistula 
underwent an associated distal pancreatectomy. 
The median number of dissected lymph nodes was 14.0 in D1 (25th–75th percentile, 8.2–
21.0) versus 31.0 in D2 (25th–75th percentile, 24.0–42.0; P < .001). The ratio between the 
number of invaded and resected lymph nodes (N index) was evaluated in both groups, and we 
observed 33.8% of patients in D2 group with N index category <20%, compared with 16.5% in 
D1 (P = .041). 
The overall 5-year survival rate was 50.4% (95% confidence interval [CI], 37.95%–62.84%) 
in D1 and 64.9% (95% CI, 53.52%–76.28%) in D2 when any cause of death was considered 
(P = .0309; Fig. 1). When mortality related only to gastric carcinoma for advanced pathologic 
tumor stages (II to IV) was considered, the 5-year survival rate in D2 was significantly higher 
(50.58%; 95% CI, 36.34%–64.82%) than in D1 (41.45%; 95% CI, 26.99%–55.91%; P = .04) 
(Fig. 2; Table 3). 
The independent prognostic factors identified by multiple Cox regression analysis are listed 
in Table 4. Hazard ratios (HRs) are expressed taking as references those categories with best 
prognosis (stages 0 and I by the 1997 tumor-node-metastasis classification, a <20% lymph 
node ratio, absence of distant metastases, intestinal histological Laurén type of tumor, and 
patients with extended [D2] lymphadenectomy). 
When we adjusted the Cox model for age, ASA index, tumor stage, presence of distant 
metastases, lymph node ratio (N index), extent of lymphadenectomy (D1 or D2), and 
associated radiotherapy, the HR for D1 versus D2 was 2.32 (95% CI, 1.25–4.30). When we 
stratified the multivariate model for the tumor stage variable (by using five categories instead 
of introducing tumor stage as an independent variable), the HR for D1 versus D2 was 2.42 
(95% CI, 1.25–4.68). 
 
 
 
DISCUSSION 
The usefulness of EL for increasing survival in patients with resectable gastric cancer is 
probably the most controversial topic in the surgical management of this disease. The EL 
technique, which involves the dissection of more nodes than those invaded by the tumor, was 
first described and used by Japanese surgeons4 as a radical surgical treatment for resectable 
gastric cancer and resulted in increased survival rates. 
Gastric cancer recurrence patterns (50% of recurrences take place in regional lymph 
nodes16) and the good Japanese clinical results seemed to confirm the benefits of this 
technique. Several nonrandomized Japanese studies2,3,17–19 showed a 5-year survival rate as 
high as 50% or 75% (depending on whether there was tumoral invasion of the regional lymph 
nodes) when an EL was performed. 
Because these data were significantly better than any Western series published,6,20 the EL 
technique began to be applied by Western surgeons, who, however, observed an increased 
postoperative morbidity without improved survival rates. Given these conflicting results, two 
large multicenter randomized studies7,8 were performed and demonstrated no survival benefit 
with EL. At the same time, several Western authors published nonrandomized studies21–25 
performed in specialized gastric cancer surgery centers, and these showed a higher survival 
rate. 
In our study, we retrospectively analyzed 156 patients with resected gastric cancer operated 
on in a single institution by the same group of 3 surgeons. Eighty-one underwent a D1 
lymphadenectomy, and 71 underwent an extended (D2) lymphadenectomy consisting of 
excision of the N1 and N2 Japanese classification lymph node levels4 and those located along 
the hepatoduodenal ligament, as well as a sampling of para-aortic, retropancreatic, and 
mesenteric nodes. 
We studied two well-balanced groups that differed only in age, ASA index, type of 
gastrectomy, and associated radiotherapy. No systematic criteria were used to assign patients 
to a group. We have ample reason to think that no bias existed in the assignment of patients to 
each group. In addition, we applied a multivariate Cox model to control for confounding, 
adjusting for all the potential prognostic variables and stratifying for tumor stage.15 
In relation to postoperative morbidity, we did not find any significant difference between the 
D1 and D2 groups. Operative differences observed (duration of surgery and production and 
maintenance of drains) did not imply a longer hospital stay in D2 (13.1 days) than in D1 (12.1 
days), unlike data published by other authors.7,8,26 
Overall morbidity was similar in D1 (48%) and D2 (53%); although these figures were 
apparently higher than those reported, this is because lesser complications are included (such 
as abdominal collections that did not need to be drained, urine infections, phlebitis, and so on). 
Despite this, the hospital stay (13 days) remains as short and the mortality rate (2%) in our 
series remains as low as data published by other gastric surgery specialty groups.5,22,23,25 
The association of gastrectomy with other organ resection (such as splenectomy or 
pancreatectomy) has been related to an increased number of complications.20 In our study, we 
extended the resection to other organs (colon, liver, or pancreas) when the surgeon observed 
macroscopic infiltration during the operation in the context of a theoretically R0 resection, 
because this is generally accepted. Nevertheless, we systematically performed splenectomy 
on all patients submitted to total gastrectomy without observing a higher morbidity, unlike other 
authors.27 
The overall mortality rate (2%, corresponding to two patients in the D1 group who died) was 
lower than that published by the large multicenter prospective trials.7,8 It seems that the greater 
specialization of the surgical team plays an important role in considering EL a safe procedure. 
 
 
 
 
 
 
 
 
 
 
 
In our study, we observed that with the D2 operation, the 5-year survival in patients with 
tumor stages >I was higher (50.6%) than in the D1 group (41.4%). Multivariate analysis 
identified D2 lymphadenectomy as one of the five independent prognostic factors. Patients 
submitted to EL (D2) had a 2.32 times lower risk of tumoral death than those receiving D1, 
independent of tumor stage. The following variables were identified as other independent 
prognostic factors: pathologic tumor stage (patients with tumor-node-metastasis stages >I 
had a 11.66 times higher rate of mortality than those with stages 0 and I), Laurén histological 
classification (gastric-type tumors presented a worse prognosis than intestinal types), N 
index (patients with an N index category <20% showed a better prognosis), and the 
presence of distant metastases (referring to patients with positive peritoneal lavage cytology, 
invaded hepatoduodenal ligament lymph nodes, or macroscopic localized carcinomatosis at 
the bursa omentalis). 
The median survival follow-up was 37 months; although it is necessary to observe longer-
term results, data obtained in our study have relevance if we consider that most tumor 
recurrences occur within the first 2 years of surgical treatment. These encouraging results are 
consistent with those observed by Siewert et al.23 and with most Japanese series,2,3,17–19 but 
they differ from the recently published results of randomized multicenter trials.6,20 
 
Recently the Dutch7 and the British (Medical Research Council)8 multicenter randomized 
studies concluded firmly that D2 is not a safe procedure and does not bring any advantage in 
the surgical treatment of gastric cancer. The Dutch study7 randomized 711 patients with 
resectable gastric cancer operated on in 80 different hospitals over 4 years, and it reported 
similar 5-year survival rates in the D1 and D2 groups (45% and 43%, respectively). Despite 
being a theoretically well-designed study (supervised by experienced Japanese surgeons), 
they found 51% of protocol violations (defined as the absence of lymph nodes from more than 
two lymph node stations that were supposed to be harvested). The Medical Research Council8 
studied 400 patients treated with D1 and D2 and obtained no difference in 5-year survival 
(35% and 33%, respectively); nevertheless, their low median number of dissected lymph 
nodes (17 in D2 and 13 in D1) is the weak point of that study, because it is generally accepted 
nowadays that a correct lymphadenectomy must harvest at least a median of 25 lymph 
nodes.23,28 
In our study, the median number of dissected lymph nodes in D2 was 31 and 14 in D1. 
These data are similar to some recently published series and are of great importance because 
the number of excised lymph nodes is considered as the quality control for a correct lymphad-
enectomy29 (the last 1997 tumor-node-metastasis classification13 established a total number of 
15 dissected nodes as necessary to properly stage gastric adenocarcinoma). Indeed, some 
authors9 assert that EL should be used in any patient with resectable gastric cancer simply 
because it permits a better staging of this disease, be-cause the stage migration 
phenomenon cannot be demonstrated. 
Both of these prospective multicenter studies6,20 are good examples of how difficult 
randomizing a complex technique can be. They collected a large number of short experiences 
by many different surgeons and hospitals (80 hospitals in the Dutch study and 35 in the British 
study), and the likely bias of pooling in these studies might be larger than that of 
nonrandomized ones. 
Although we used a nonrandomized design, our study has the strength of being conducted in 
a single institution (avoiding the problem of protocol violations) and comparing two well-
balanced groups. In addition, we used a multivariate analysis to determine independent 
prognostic variables. The fact that the type of lymph node dissection performed has been 
identified as one of the main determinants of survival could add evidence to solve the dilemma 
about the benefits of lymphadenectomy, be-cause nowadays it is not always possible or 
ethically correct to randomize patients to a treatment when the application of a different 
oncologic therapeutic procedure offers unequal results. Our results suggest that EL should be 
the procedure of choice in the management of resectable gastric cancer at any location, 
provided that adequate morbidity and mortality figures are maintained. 
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TABLE 1. Characteristics of 156 patients with resected 
gastric cancer according to the extent of lymphadenectomy 
 
Variable 
D1 (n = 85) 
(%) 
D2 (n = 71) P 
(%) valuea 
Age, y, mean (SD) 63.7 (11.3) 55.6 (11.4) <.001 
Male (%) 68 (80.0) 51 (71.8) .232 
ASA index 
  
<.001 
I 44 (51.8) 58 (81.7) 
 
II 34 (40.0) 13 (18.3) 
 
III 7 (8.2) – 
 
Laure~n histological typeb 
  
.492 
Gastric 45 (49.4) 44 (58.0) 
 
Intestinal 38 (45.8) 25 (36.2) 
 
Location of tumor 
  
.318 
Proximal 16 (18.8) 12 (16.9) 
 
Middle 20 (23.5) 21 (29.6) 
 
Distal 42 (49.5) 27 (38.0) 
 
More than two thirds of stomach 7 (8.2) 11 (15.5) 
 
Tumor size (cm) 
  
.744 
<-5 25 (29.4) 21 (29.6) 
 
>5 53 (70.6) 50 (70.4) 
 
Depth of tumor invasion (T) 
  
.902 
Tis 4 (4.7) 2 (2.9) 
 
T1 21 (24.8) 17 (23.9) 
 
T2 8 (9.4) 5 (7.0) 
 
T3 41 (48.2) 35 (49.3) 
 
T4 11 (12.9) 12 (16.9) 
 
Regional node invasion (N) 
  
.445 
N0 38 (44.7) 26 (36.6) 
 
N1 29 (34.1) 22 (31.0) 
 
N2 11 (13.0) 13 (18.3) 
 
N3 7 (8.2) 10 (14.1) 
 
Distant metastases (M) 
  
.251 
M0 74 (87.1) 57 (80.3) 
 
M1 11 (12.9) 14 (19.7) 
 
Pathologic tumor staging (TNM 1997) 
 
.871 
0 4 (4.7) 2 (2.8) 
 
I 
   
IA 19 (22.4) 10 (14.1) 
 
IB 7 (8.2) 8 (11.3) 
 
II 10 (11.8) 9 (12.7) 
 
III 
   
IIIA 19 (22.4) 17 (23.9) 
 
IIIB 6 (7.0) 6 (8.5) 
 
IV 20 (23.5) 19 (26.7) 
 
Gastrectomy (type of resection) 
   
Total 37 (43.5) 71 (100) <.001 
Subtotal 48 (56.5) – 
 
Extended surgery 8 (9.4) 9 (12.6) .514 
Pancreas 3 (3.5) 6 (8.4) 
 
Colon 2 (2.4) 3 (4.2) 
 
Liver 3 (3.5) – 
 
Radiotherapy 23 (27.1) 33 (46.5) .012 
Chemotherapy 28 (32.9) 20 (28.2) .520 


	
	
				

	

	X

	
		 !"	#$%"	$















	
				


$		#

 %% &%''(%)* %+% &%%'(%,'* +'-
.#
 	
!&/*

  01  2+2 2%%
3
  %0%  10 -)

	#	
     
	  )0  )1 

	  )0  %22 
  )0  %- 
  +  %0 
		
4  %%  ( 
5
  +  %0 
#     
5
  1  %- 
6		
  2)  0 
6	  2)  )1 
!  2)  2- 
7
	  +2  2- 
.


  2)  2- 
#	#	  +0%  02' %-
8	

  %%1  1 '+,
!  %)  %1+ +22
!#
  1  10 
!#  0,  ,% 
.
  (  1 

  0  12 %0+
$  2)  2- %'''
9	#  (  1 
$	  +2  1 
3
  %  ( 
5		  %  ( 
9	#	  +2  ( 
9 
	  +2  1 
:		  2)  %0 
.#
 	



 +  ' )2



!
	;
4	
:

&2(,2#
*

	
!
#	#	
!#
 	

	
#	#



.#
 	
!
	#"	
+'#		#
 






























		

	
	 ! "##$
%"&'
()&!*)	+	,	-	-			



' 0 %''  %''
 %) ,2 %' %''
6 , %'' 1 %''
 %' %'' ) %''
 %) 2'' %, ,-'
6 - ( - (
< ' %,+ %) %)
'' 2 %'' + %''
%' + %'' % %''
+'' , ,%0 1 1,2
+%' %, 2') %2 ,,







	 !	
2

  			"##
	"%2	
	
$%00		
$









			.		-	





			
 8=

	)2/5 
			
&*
'(% %&>*
>% %%-- %0+()0)0''2
?#	
	&4*
<'/ %&>*
?'/ 021 %,,(%%,)''
$&*
' %&>*
% ++, %,(--+'''2
?
@	
 %&>*
3
 ,1 %0,(22''')
94	#	
&$*
94&$* %&>*
?&$%* + %2(0+''',







5	
 	
	>

 

?A		 
	  	
   
 	#
	 	 =
 
	 &5	4 	*  	 "
B	
  
!	"!	
&
*  4&
	
*
	
	
#&C	*

: 	#'%		

	
	
&
<*

4= !
#	  !	!
	#	<'/?'/

%#	 #
	  #		#		
	=
		
!
	

; 

  	
	 
	












































; 

  	
	
	

	&	
	DE
F*
